A new use for an old drug provides dual glucose and LDL-lowering therapy in the modern setting of T2D management: colesevelam HCL.
Goldberg
Ronald B
RB
Division of Endocrinology, Diabetes and Metabolism, Diabetes Research Institute, University of Miami Miller School of Medicine, 1450 Northwest 10th Avenue, Miami, FL 33136, USA. rgoldber@med.miami.edu
D000499:Allylamine / Q000031:analogs & derivatives* / Q000627:therapeutic use; D000924:Anticholesteremic Agents / Q000627:therapeutic use*; D001647:Bile Acids and Salts / Q000378:metabolism; D002316:Cardiotonic Agents / Q000627:therapeutic use; D008078:Cholesterol, LDL / Q000378:metabolism*; D000069472:Colesevelam Hydrochloride; D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy*; D006801:Humans; D007004:Hypoglycemic Agents / Q000627:therapeutic use*
D000924:Anticholesteremic Agents; D001647:Bile Acids and Salts; D002316:Cardiotonic Agents; D008078:Cholesterol, LDL; D007004:Hypoglycemic Agents; D000499:Allylamine; D000069472:Colesevelam Hydrochloride